280 related articles for article (PubMed ID: 37512088)
1. A Novel Notch-Related Gene Signature for Prognosis and Immune Response Prediction in Ovarian Cancer.
Pi Y; Sun F; Zhang Z; Liu X; Lou G
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512088
[No Abstract] [Full Text] [Related]
2. Identification and validation of pyroptosis-related gene landscape in prognosis and immunotherapy of ovarian cancer.
Gao L; Ying F; Cai J; Peng M; Xiao M; Sun S; Zeng Y; Xiong Z; Cai L; Gao R; Wang Z
J Ovarian Res; 2023 Jan; 16(1):27. PubMed ID: 36707884
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer subtypes based on the regulatory genes of RNA modifications: Novel prediction model of prognosis.
Zheng P; Li N; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972341. PubMed ID: 36545327
[TBL] [Abstract][Full Text] [Related]
4. Identification of an Autophagy-Related Signature for Prognosis and Immunotherapy Response Prediction in Ovarian Cancer.
Ding J; Wang C; Sun Y; Guo J; Liu S; Cheng Z
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830707
[TBL] [Abstract][Full Text] [Related]
5. A signature based on glycosyltransferase genes provides a promising tool for the prediction of prognosis and immunotherapy responsiveness in ovarian cancer.
Xu X; Wu Y; Jia G; Zhu Q; Li D; Xie K
J Ovarian Res; 2023 Jan; 16(1):5. PubMed ID: 36611197
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
7. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
8. A signature based on anoikis-related genes for the evaluation of prognosis, immunoinfiltration, mutation, and therapeutic response in ovarian cancer.
Duan Y; Xu X
Front Endocrinol (Lausanne); 2023; 14():1193622. PubMed ID: 37383389
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation-related genes mediated prognostic signature contribute to prognostic prediction and treatment options in ovarian cancer: based on bulk and single‑cell RNA sequencing data.
You Y; Yang Q
BMC Cancer; 2024 Feb; 24(1):207. PubMed ID: 38355446
[TBL] [Abstract][Full Text] [Related]
10. Novel immune-related gene signature for risk stratification and prognosis prediction in ovarian cancer.
Fei H; Han X; Wang Y; Li S
J Ovarian Res; 2023 Oct; 16(1):205. PubMed ID: 37858138
[TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a transcription factors-based prognostic signature for ovarian cancer.
Cheng Q; Li L; Yu M
J Ovarian Res; 2022 Feb; 15(1):29. PubMed ID: 35227285
[TBL] [Abstract][Full Text] [Related]
12. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
[TBL] [Abstract][Full Text] [Related]
13. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract][Full Text] [Related]
14. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
15. Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer.
Zhao S; Zhang X; Gao F; Chi H; Zhang J; Xia Z; Cheng C; Liu J
Front Endocrinol (Lausanne); 2023; 14():1145797. PubMed ID: 36950684
[TBL] [Abstract][Full Text] [Related]
16. Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer.
Liu Y; Liu S; Yan L; Zhang Q; Liu W; Huang X; Liu S
Mediators Inflamm; 2023; 2023():1400267. PubMed ID: 38022687
[TBL] [Abstract][Full Text] [Related]
17. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unveils heterogeneity and establishes a novel signature for prognosis and tumor immune microenvironment in ovarian cancer.
Wang Z; Zhang J; Dai F; Li B; Cheng Y
J Ovarian Res; 2023 Jan; 16(1):12. PubMed ID: 36642706
[TBL] [Abstract][Full Text] [Related]
19. Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer.
Liu L; Wang Q; Zhou JY; Zhang B
J Ovarian Res; 2023 Apr; 16(1):88. PubMed ID: 37122030
[TBL] [Abstract][Full Text] [Related]
20. Development of a necroptosis-related gene signature and the immune landscape in ovarian cancer.
Nie S; Ni N; Chen N; Gong M; Feng E; Liu J; Liu Q
J Ovarian Res; 2023 Apr; 16(1):82. PubMed ID: 37095524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
